Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOIIW) Change in Acquisitions & Divestments (2023 - 2024)

Oncology Institute posted quarterly Change in Acquisitions & Divestments of $10.0 million for Q3 2024, up 16.62% year-on-year from $8.6 million in Q4 2023, and down 50.0% on a QoQ basis from $20.0 million in Q2 2024.

Oncology Institute (TOIIW) has 2 years of Change in Acquisitions & Divestments data on file, last reported at $10.0 million in Q3 2024.

  • For the quarter ending Q3 2024, Change in Acquisitions & Divestments rose 16.62% year-over-year to $10.0 million; the trailing twelve-month figure through Jun 2025 stood at $10.0 million (down 83.64% YoY), and the FY2024 full-year result was $50.0 million, down 38.47% from the prior year.
  • Change in Acquisitions & Divestments for Q3 2024 stood at $10.0 million, down from $20.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $30.1 million in Q2 2023 and bottomed at $8.6 million in Q3 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn
10 Oncology Institute - - 139.16 Mn

Historic Data

Download Data 🔒
DateValue
Sep 30, 2024 10.00 Mn
Sep 30, 2024 10.00 Mn
Jun 30, 2024 20.00 Mn
Jun 30, 2024 20.00 Mn
Mar 31, 2024 20.00 Mn
Mar 31, 2024 20.00 Mn
Dec 31, 2023 12.56 Mn
Dec 31, 2023 12.56 Mn
Sep 30, 2023 8.58 Mn
Sep 30, 2023 8.58 Mn
Jun 30, 2023 30.13 Mn
Jun 30, 2023 30.13 Mn
Mar 31, 2023 30.00 Mn
Mar 31, 2023 30.00 Mn